Market Access News | pharmaphorum

News

Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.

News

Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.

News

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form.

News

Trade body PhRMA is among the organisations contributing to what looks like record inaugural fundraising for incoming US President Donald Trump.

News

AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.

News

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.